Literature DB >> 31209876

Energetic drain driving hypertrophic cardiomyopathy.

Vasco Sequeira1, Edoardo Bertero1, Christoph Maack1.   

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common form of hereditary cardiomyopathy and is mainly caused by mutations of genes encoding cardiac sarcomeric proteins. HCM is characterized by hypertrophy of the left ventricle, frequently involving the septum, that is not explained solely by loading conditions. HCM has a heterogeneous clinical profile, but diastolic dysfunction and ventricular arrhythmias represent two dominant features of the disease. Preclinical evidence indicates that the enhanced Calcium (Ca2+ ) sensitivity of the myofilaments plays a key role in the pathophysiology of HCM. Notably, this is not always a direct consequence of sarcomeric mutations, but can also result from secondary mutation-driven alterations. Here, we review experimental and clinical evidence indicating that increased myofilament Ca2+ sensitivity lies upstream of numerous cellular derangements which potentially contribute to the progression of HCM toward heart failure and sudden cardiac death.
© 2019 Federation of European Biochemical Societies.

Entities:  

Keywords:  cellular ADP elevation; energetic mismatch; high diastolic myofilament activation; hypertrophic cardiomyopathy; oxidative stress

Mesh:

Substances:

Year:  2019        PMID: 31209876     DOI: 10.1002/1873-3468.13496

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  Increasing mitochondrial ATP synthesis with butyrate normalizes ADP and contractile function in metabolic heart disease.

Authors:  Marcello Panagia; Huamei He; Tomas Baka; David R Pimentel; Dominique Croteau; Markus M Bachschmid; James A Balschi; Wilson S Colucci; Ivan Luptak
Journal:  NMR Biomed       Date:  2020-02-17       Impact factor: 4.044

Review 2.  Implications of the complex biology and micro-environment of cardiac sarcomeres in the use of high affinity troponin antibodies as serum biomarkers for cardiac disorders.

Authors:  Christopher R Solaro; R John Solaro
Journal:  J Mol Cell Cardiol       Date:  2020-05-19       Impact factor: 5.000

Review 3.  The role of CD36 in cardiovascular disease.

Authors:  Hongyang Shu; Yizhong Peng; Weijian Hang; Jiali Nie; Ning Zhou; Dao Wen Wang
Journal:  Cardiovasc Res       Date:  2022-01-07       Impact factor: 10.787

Review 4.  Critical Evaluation of Current Hypotheses for the Pathogenesis of Hypertrophic Cardiomyopathy.

Authors:  Marko Ušaj; Luisa Moretto; Alf Månsson
Journal:  Int J Mol Sci       Date:  2022-02-16       Impact factor: 5.923

5.  Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument.

Authors:  Matthew Reaney; Veleka Allen; Amy J Sehnert; Liang Fang; Albert A Hagège; Srihari S Naidu; Iacopo Olivotto
Journal:  Pharmacoecon Open       Date:  2022-06-02

Review 6.  Characterization of cardiac metabolism in iPSC-derived cardiomyocytes: lessons from maturation and disease modeling.

Authors:  Jolanda van der Velden; Birgit Goversen; Sofija Vučković; Rafeeh Dinani; Edgar E Nollet; Diederik W D Kuster; Jan Willem Buikema; Riekelt H Houtkooper; Miranda Nabben
Journal:  Stem Cell Res Ther       Date:  2022-07-23       Impact factor: 8.079

7.  Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy.

Authors:  Styliani Vakrou; Yamin Liu; Li Zhu; Gabriela V Greenland; Bahadir Simsek; Virginia B Hebl; Yufan Guan; Kirubel Woldemichael; Conover C Talbot; Miguel A Aon; Ryuya Fukunaga; M Roselle Abraham
Journal:  Sci Rep       Date:  2021-06-23       Impact factor: 4.996

Review 8.  Unraveling the Genotype-Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesity-Related Cardiac Defects as a Major Disease Modifier.

Authors:  Edgar E Nollet; B Daan Westenbrink; Rudolf A de Boer; Diederik W D Kuster; Jolanda van der Velden
Journal:  J Am Heart Assoc       Date:  2020-11-11       Impact factor: 6.106

Review 9.  LncRNAs in cardiac hypertrophy: From basic science to clinical application.

Authors:  Lei Liu; Donghui Zhang; Yifei Li
Journal:  J Cell Mol Med       Date:  2020-09-08       Impact factor: 5.310

10.  Whole-exome sequencing reveals MYH7 p.R671C mutation in three different phenotypes of familial hypertrophic cardiomyopathy.

Authors:  Wei Yu; Mi-Mi Huang; Guo-Hong Zhang; Wei Wang; Chun-Juan Chen; Ji-Dong Cheng
Journal:  Exp Ther Med       Date:  2021-07-15       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.